Effect of systemic β-agonist therapy on IgE production in allergic subjects in vivo

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 5, 1998, Pages 727-731

  Corne, Jonathan M ^a,d   Linaker, Catherine H ^a   Howarth, Peter H ^a   Lau, Laurie C K ^a   Merrett, Terrence ^b   Beasely, Richard ^c   Church, Martin ^a  

^a University Medicine   (United Kingdom)

^b Allergy Analysis Centre   (United Kingdom)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Allergic rhinitis; IgE; Salbutamol

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN E; SALBUTAMOL SULFATE;

ADULT; ALLERGIC RHINITIS; ANTIBODY PRODUCTION; ARTICLE; ATOPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GRASS POLLEN; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASONAL VARIATION;

EID: 0031756599     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70011-9     Document Type: Article

References (27)

1. Lowell F, Curry J, Schiller I. A clinical and experimental study of isoprel in spontaneous and induced asthma. N Engl J Med 1949;240:45-51.
2. van Metre T. Adverse effects of inhalation of excessive amounts of nebulised isoproterenol in status asthmaticus. J Allergy 1969;43:101-13.
3. Cockcroft D, McParland C, Britto S, Swystun V, Rutherford B. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993;342:833-7.
4. Vathenen A, Knox A, Higgins B, Britton J, Tattersfield A. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988;1:554-8.
5. Trembath P, Greenacre J, Anderson M, Dimmock S, Mansfield L, Wardsworth J, et al. Comparison of four weeks treatment with fenoterol and terbutaline aerosols in adult asthmatics. A double-blind cross-over study. J Allergy Clin Immunol 1979;63:395-400.
6. Taylor D, Sears M, Herbison G, Flannery E, Print C, Lake D, et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 1993;48:134-8.
7. Sears M, Taylor R, Print C, Lake D, Li Q, Flannery E, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990;336:1391-6.
8. International Asthma Consensus Report. Clin Exp Allergy 1992;22:1-72.
9. van der Molen T, Postma D, Turner M, Jong B, Malo J, Chapman K, et al. Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators. Thorax 1997;522:535-9.
10. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br Med J 1993;306:1034-7.
11. Meier C, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax 1997;52:612-7.
12. Kesten S, Chapman K, Broder I, Cartier A, Hyland R, Knight A, et al. Sustained improvement in asthma with long-term use of formoterol fumarate. Ann Allergy 1992;69:415-20.
13. Sears M, Rea H. Patients at risk of dying of asthma: New Zealand experience. J Allergy Clin Immunol 1987;80:477-81.
14. Conolly M, Davies D, Dollery C, George C. Resistance to β-adrenoceptor stimulants (a possible explanation for the rise in asthma deaths). Br J Pharmacol 1971;43:389-402.
15. Chung K. The current debate concerning β-agonists in asthma: a review. J R Soc Med 1993;86:96-100.
16. Paul-Eugene N, Kolb JP, Calenda A, Gordon J, Kikutani H, Kishimoto T, et al. Functional interaction between β2-adrenoceptor agonists and interleukin-4 in the regulation of CD23 expression and release and IgE production in human. Mol Immunol 1993;30:157-64.
17. Coqueret O, Dugas B, Mencia-Huerta JM, Braquet P. Regulation of IgE production from human mononuclear cells by β2-adrenoreceptor agonist. Clin Exp Allergy 1995;25:304-11.
18. Sears MR, Burrows B, Flannery EM, Herbison GP, Hewitt CJ, Holdaway MD. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991;325:1067-71.
19. Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin test reactivity to allergens. N Engl J Med 1989;320:271-7.
20. Pollart S, Chapman M, Fiocco G, Rose G, Platts-Mills A. Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. J Allergy Clin Immunol 1989;83:875-82.
21. Babson A. The IMMULITE automated immunoassay system. J Clin Immunoassay 1991;14:83-8.
22. Lichtenstein L, Ishizaka K, Norman P, Sobotka A, Hill B. IgE antibody measurements in ragweed hay fever. J Clin Invest 1973;52:472-82.
23. Naclerio RM, Adkinson NF Jr, Creticos PS, Baroody FM, Hamilton RG, Norman PS. Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin E antibodies. J Allergy Clin Immunol 1993;92:717-21.
24. Sykes R, Reese M, Meyer M, Chubb J. Relative bioavailability of a controlled-release albuterol formulation for twice-daily use. Biopharm Drug Dispos 1988;9:551-6.
25. Qing F, Hayes F, Rhodes C, Ind P, Jones T, Hughes J. Effects of chronic salbutamol therapy on human β adrenergic receptors (βAR): peripheral mononuclear leukocytes compared with lung tissue. Thorax 1994;49:1046P.
26. Durham S, Gould H, Thienes C, Jacobson M, Masuyama K, Rak S, et al. Expression of ε-germ line gene transcripts and mRNA for the e-heavy chain of IgE in nasal B cells and the effects of topical corticosteroids. Eur J Immunol 1997;27:2899-906.
27. Borum P, Schultz Larsen F. Seasonal allergic rhinitis treated with a beta-2-adrenostimulant. Allergy 1987;42:141-5.